Literature DB >> 35932325

A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate.

Kazutoshi Ebisawa1, Yosuke Masamoto1, Koichi Yagi2, Mineo Kurokawa3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35932325     DOI: 10.1007/s00277-022-04940-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   4.030


× No keyword cloud information.
  2 in total

1.  [Role of PDGF/PDGFR Pathway in Essential Thrombocythemia and Its Action Mechanism].

Authors:  Li-Xia Zhou; En-Yu Liang; Jie-Yu Ye; Mo Yang
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2016-04

2.  Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Biologics       Date:  2007-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.